Acquired Genetic Alterations in Tumor Cells Dictate the Development of High-risk Neuroblastoma and Clinical Outcomes

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2015 Jul 11

PMID 26159519

Citations 37

Authors

Faizan H Khan

Vijayabaskar Pandian

Satishkumar Ramraj

Mohan Natarajan

Sheeja Aravindan

Terence S Herman

Natarajan Aravindan

Affiliations

Soon will be listed here.

Abstract

Background: Determining the driving factors and molecular flow-through that define the switch from favorable to aggressive high-risk disease is critical to the betterment of neuroblastoma cure.

Methods: In this study, we examined the cytogenetic and tumorigenic physiognomies of distinct population of metastatic site- derived aggressive cells (MSDACs) from high-risk tumors, and showed the influence of acquired genetic rearrangements on poor patient outcomes.

Results: Karyotyping in SH-SY5Y and MSDACs revealed trisomy of 1q, with additional non-random chromosomal rearrangements on 1q32, 8p23, 9q34, 15q24, 22q13 (additions), and 7q32 (deletion). Array CGH analysis of individual clones of MSDACs revealed genetic alterations in chromosomes 1, 7, 8, and 22, corresponding to a gain in the copy numbers of LOC100288142, CD1C, CFHR3, FOXP2, MDFIC, RALYL, CSMD3, SAMD12-AS1, and MAL2, and a loss in ADAM5, LOC400927, APOBEC3B, RPL3, MGAT3, SLC25A17, EP300, L3MBTL2, SERHL, POLDIP3, A4GALT, and TTLL1. QPCR analysis and immunoblotting showed a definite association between DNA-copy number changes and matching transcriptional/translational expression in clones of MSDACs. Further, MSDACs exert a stem-like phenotype. Under serum-free conditions, MSDACs demonstrated profound tumorosphere formation ex vivo. Moreover, MSDACs exhibited high tumorigenic capacity in vivo and prompted aggressive metastatic disease. Tissue microarray analysis coupled with automated IHC revealed significant association of RALYL to the tumor grade in a cohort of 25 neuroblastoma patients. Clinical outcome association analysis showed a strong correlation between the expression of CFHR3, CSMD3, MDFIC, FOXP2, RALYL, POLDIP3, SLC25A17, SERHL, MGAT3, TTLL1, or LOC400927 and overall and relapse-free survival in patients with neuroblastoma.

Conclusion: Together, these data highlight the ongoing acquired genetic rearrangements in undifferentiated tumor-forming neural crest cells, and suggest that these alterations could switch favorable neuroblastoma to high-risk aggressive disease, promoting poor clinical outcomes.

Citing Articles

SLC25A17 inhibits autophagy to promote triple-negative breast cancer tumorigenesis by ROS-mediated JAK2/STAT3 signaling pathway.

Zhou H, Li J, He Y, Xia X, Liu J, Xiong H Cancer Cell Int. 2024; 24(1):85.

PMID: 38402166 PMC: 10893722. DOI: 10.1186/s12935-024-03270-z.

Multiomics data analyses to identify SLC25A17 as a novel biomarker to predict the prognosis and immune microenvironment in head and neck squamous cell carcinoma.

Shi Y, Huang J, Hu Y, Shen Y BMC Bioinformatics. 2023; 24(1):269.

PMID: 37386359 PMC: 10308725. DOI: 10.1186/s12859-023-05399-6.

The MAL Family of Proteins: Normal Function, Expression in Cancer, and Potential Use as Cancer Biomarkers.

Labat-de-Hoz L, Rubio-Ramos A, Correas I, Alonso M Cancers (Basel). 2023; 15(10).

PMID: 37345137 PMC: 10216460. DOI: 10.3390/cancers15102801.

The polymerase δ-interacting protein family and their emerging roles in diseases.

Huang P, Wu L, Zhu N, Zhao H, Du J Front Med (Lausanne). 2022; 9:1026931.

PMID: 36425112 PMC: 9679015. DOI: 10.3389/fmed.2022.1026931.

FOXP2 regulates thyroid cancer cell proliferation and apoptosis via transcriptional activation of RPS6KA6.

Yang F, Xiao Z, Zhang S Exp Ther Med. 2022; 23(6):434.

PMID: 35607372 PMC: 9121208. DOI: 10.3892/etm.2022.11361.

References

Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M . Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 2009; 45(16):2835-42. DOI: 10.1016/j.ejca.2009.06.010. View

Sandberg A, Meloni-Ehrig A . Cytogenetics and genetics of human cancer: methods and accomplishments. Cancer Genet Cytogenet. 2010; 203(2):102-26. DOI: 10.1016/j.cancergencyto.2010.10.004. View

George R, Attiyeh E, Li S, Moreau L, Neuberg D, Li C . Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One. 2007; 2(2):e255. PMC: 1797488. DOI: 10.1371/journal.pone.0000255. View

van Roy N, Van Limbergen H, Vandesompele J, Van Gele M, Poppe B, Salwen H . Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines. Genes Chromosomes Cancer. 2001; 32(2):126-35. DOI: 10.1002/gcc.1174. View

Kryh H, Caren H, Erichsen J, Sjoberg R, Abrahamsson J, Kogner P . Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC Genomics. 2011; 12:443. PMC: 3178547. DOI: 10.1186/1471-2164-12-443. View

Fidler I . Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 1990; 50(19):6130-8. View

George R, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger R . High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006; 24(18):2891-6. DOI: 10.1200/JCO.2006.05.6986. View

Spengler B, Biedler J, Ross R . A corrected karyotype for the SH-SY5Y human neuroblastoma cell line. Cancer Genet Cytogenet. 2002; 138(2):177-8. DOI: 10.1016/s0165-4608(02)00523-x. View

Chen C, Chiou S, Huang C, Jan C, Lin S, Tsai M . Distinct population of highly malignant cells in a head and neck squamous cell carcinoma cell line established by xenograft model. J Biomed Sci. 2009; 16:100. PMC: 2785774. DOI: 10.1186/1423-0127-16-100. View

10.

Khan F, Ganesan P, Kumar S . Y Chromosome microdeletion and altered sperm quality in human males with high concentration of seminal hexachlorocyclohexane (HCH). Chemosphere. 2010; 80(9):972-7. DOI: 10.1016/j.chemosphere.2010.05.047. View

11.

Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D, Wicha M . Cancer stem cells in breast: current opinion and future challenges. Pathobiology. 2008; 75(2):75-84. PMC: 2789397. DOI: 10.1159/000123845. View

12.

Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G . Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol. 2010; 28(19):3122-30. DOI: 10.1200/JCO.2009.26.7955. View

13.

Weinstein J, Katzenstein H, Cohn S . Advances in the diagnosis and treatment of neuroblastoma. Oncologist. 2003; 8(3):278-92. DOI: 10.1634/theoncologist.8-3-278. View

14.

Cavenee W, Dryja T, Phillips R, Benedict W, Godbout R, Gallie B . Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature. 1983; 305(5937):779-84. DOI: 10.1038/305779a0. View

15.

Chen K, Huang Y, Chen J . Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013; 34(6):732-40. PMC: 3674516. DOI: 10.1038/aps.2013.27. View

16.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

17.

Land H, Parada L, Weinberg R . Cellular oncogenes and multistep carcinogenesis. Science. 1983; 222(4625):771-8. DOI: 10.1126/science.6356358. View

18.

Yokota J . Tumor progression and metastasis. Carcinogenesis. 2000; 21(3):497-503. DOI: 10.1093/carcin/21.3.497. View

19.

Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B . Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer. 2011; 56(4):578-83. DOI: 10.1002/pbc.22693. View

20.

Khan F, Pandian V, Ramraj S, Aravindan S, Herman T, Aravindan N . Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells. BMC Genomics. 2015; 16:501. PMC: 4491873. DOI: 10.1186/s12864-015-1642-x. View